Ratings Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Market Closed - Nasdaq Other stock markets 04:00:02 2024-04-18 pm EDT			5-day change	1st Jan Change
37.82 ^USD	-0.53%		-3.81%	+2.33%

Apr. 18	Halozyme Therapeutics Insider Sold Shares Worth $768,390, According to a Recent SEC Filing	MT
Mar. 13	Halozyme Therapeutics Insider Sold Shares Worth $839,100, According to a Recent SEC Filing	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
The company's profit outlook over the next few years is a strong asset.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
The company has a low valuation given the cash flows generated by its activity.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Analyst opinion has improved significantly over the past four months.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

The group shows a rather high level of debt in proportion to its EBITDA.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
HALOZYME THERAPEUTICS, INC.	+2.33%	4.83B	A-
VERTEX PHARMACEUTICALS INCORPORATED	-3.30%	102B	B+
REGENERON PHARMACEUTICALS, INC.	+1.79%	96.84B	B+
ARGENX SE	-0.44%	21.48B	B
BIONTECH SE	-18.35%	20.82B	B+
GENMAB A/S	-7.45%	18.6B	A-
WUXI APPTEC CO., LTD.	-40.31%	16.81B	A-
BEIGENE, LTD.	-26.84%	13.78B	B
NEUROCRINE BIOSCIENCES, INC.	+0.59%	13.4B	C+
SAREPTA THERAPEUTICS, INC.	+20.86%	11.06B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes